Bepridil
A calcium channel blocker.
General information
Bepridil is a non-selective calcium channel blocker. It also acts as a calmodulin inhibitor. It has well-studied anti-anginal properties. It manifests also vasodilatory, anti-hypertensive, and selective anti-arrhythmia activities. Bepridil use is limited due to its possible involvement in ventricular arrhythmias (DrugBank).
Bepridil on PubChem
Bepridil on Wikipedia
Marketed as
ANGOPRIL; CORDIUM; VASCOR
CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Bepridil is potent against SARS-CoV-2 in vitro
3CLpro Small molecule Enzyme assay In vitro In silico |
in silico; in vitro enzyme assay; Vero E6 cells; A459/ACE2 cells; SARS-CoV-2 live virus | 9.41 | Inhibited SARS-CoV-2 3C-like protease with an IC50 of ca. 72 µM in vitro. Completely prevented SARS-CoV-2-induced cytopathic effect in cell cultures at 6.25 μM with estimated EC50s of 0.86 and 0.46 μM in Vero E6 and A549/ACE2 cells, respectively. It did not manifest toxicity in the cell cultures in concentrations up to 25 and 50 μM in Vero E6 and A549/ACE2 cells, respectively. |
Feb/17/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition
|
Dec/04/2020 |
|
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.
|
Feb/02/2022 |
